Abstract 155P
Background
Increased mean platelet volume (MPV), an early marker of platelet activation has been shown to be associated with the pathophysiology of various cancers. However, studies analyzing the prognostic effect of MPV [Disease free survival (DFS) and Overall survival (OS)] in carcinoma stomach are lacking. This study was done to analyze the effect of MPV on DFS and OS of resectable carcinoma stomach patients.
Methods
Retrospective analysis of the data of 143 consecutively resected gastrectomy patients between 2009- 13 was done. Associations between MPV and Clinicopathological factors were assessed. DFS and OS for 5 years were analyzed using the Kaplan-Meier curve.MPV of 10.5 femtolitres (fl) yielded maximum combined sensitivity and specificity on ROC curve. The area under curve(AUC) for MPV was 0.611. Therefore Preoperative cut-off value of MPV was taken as 10.5 fl. Differences between survival curves were tested for statistical significance using the log-rank test.
Results
Mean OS in the group with preoperative MPV < 10.5 vs > 10.5 was 59.3 vs 41.3 mts (95% CI = 58.81 – 60 vs 37.87 - 44.94; P = <0.0001). Mean OS in the group with postoperative (after one month) of MPV< 10.5 vs > 10.5 was 37.9 vs 29.2 mts (95% CI = 32-43.8vs 27.1- 19.8; P = <0.0001). Mean DFS in the group with preoperative MPV < 10.5 vs > 10.5 was 59.8 mts vs 38.2 mts (95% CI = 59.365-60.26 vs 31.798- 44.732; P = <0.0001). Mean DFS with postoperative (after one month) MPV< 10.5 vs > 10.5 58.0 mts vs 25.9 months (95% CI = 56.629 - 59.4 vs 20.841- 30.959; P = 0.012). These results show that MPV estimation both preoperatively and postoperative has a significant impact on both DFS and OS. And those patients who had increased MPV preoperatively had lower DFS and OS compared to those who had MPV lower at the initial presentation. Also, those patients who had initial high MPV which declined postoperatively after one month also had better DFS and OS compared to those who had persistent elevated MPV.
Conclusions
Hence MPV both preoperative and postoperative (1 month) shows to be a promising predictive factor in resectable carcinoma stomach.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract